p53 Protein expression in nevi and melanomas.

p53 Protein immunohistochemical expression is a wide-spread feature of the malignant phenotype; most melanomas are reported as p53 positive, while nevi are reported as p53 negative. We investigate a series of 75 benign nevi and 47 melanomas (40 primary and seven metastatic) to evaluate their pattern of p53 immunoreactivity with a panel of specific antibodies (PAb1801, PAb240, DO7, and CM1) in view of a possible diagnostic role of p53 immunostaining. Our results demonstrate that 15% of nevi show p53 immunoreactive nuclei (usually in less than 1% of the cells) and that 30% of melanomas show p53 immunoreactive nuclei (one case with 20% immunoreactive cells, six cases with 1% to 5% positive cells, and four cases with less than 1% positive nuclei). p53 Positivity was seen also in basal and suprabasal keratinocytes. p53 Positivity in nevi is at variance with literature data supporting that nevi are p53 negative. p53 Positivity in nevi and in epidermis may be related to mechanisms of DNA repair, apoptosis, or to a specific phase of the cell cycle. In our series, p53 expression in melanomas is not as frequent as reported in the literature. Population-based differences or differences in case selection and sample handling may account for the above discrepancies. The demonstration of p53 positivity in benign skin lesions greatly hinders the possibility of a diagnostic use of p53 immunostaining in dermatopathology.

[1]  C. Fletcher,et al.  p53 protein expression in non‐neoplastic lesions and benign and malignant neoplasms of soft tissue , 1993, Histopathology.

[2]  M. Barbareschi,et al.  p53 protein expression in basal cell carcinomas , 1992, Histopathology.

[3]  G. Serio,et al.  p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. , 1992, American journal of clinical pathology.

[4]  T. Visakorpi,et al.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. , 1992, Journal of the National Cancer Institute.

[5]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[6]  P. G. Prioleau,et al.  Overexpression of p53 protein in basal cell carcinomas of human skin. , 1992, The American journal of pathology.

[7]  P Dalla Palma,et al.  p53 protein expression in central nervous system neoplasms. , 1992, Journal of clinical pathology.

[8]  J. Bartek,et al.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.

[9]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[10]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[11]  R. Maestro,et al.  High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. , 1992, Oncogene.

[12]  M. Barbareschi,et al.  Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms , 1992, The Journal of pathology.

[13]  D. Wynford‐Thomas.  P53 in tumour pathology: Can we trust immunocytochemistry? , 1992, The Journal of pathology.

[14]  M. Balzi,et al.  Cell kinetics of melanocytes in common and dysplastic nevi and in primary and metastatic cutaneous melanoma. , 1992, Pathology, research and practice.

[15]  R. Metcalf,et al.  Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners , 1992, The Lancet.

[16]  T. Mikkelsen,et al.  Clonal expansion of p53 mutant cells is associated with brain tumour progression , 1992, Nature.

[17]  G. Merlo,et al.  Loss of heterozygosity on chromosome 17p13 in breast carcinomas identifies tumors with high proliferation index. , 1992, The American journal of pathology.

[18]  A. Gown,et al.  Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. , 1992, The American journal of pathology.

[19]  J. Bartek,et al.  Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. , 1992, Journal of cell science.

[20]  M. Bellman,et al.  Infantile spasms: a price for ignoring parental anxiety? , 1991, The Lancet.

[21]  E. Heyderman,et al.  p53 immunostaining in benign breast disease , 1991, The Lancet.

[22]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[23]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Harris,et al.  Expression of mutant p53 in melanoma. , 1991, Cancer research.

[25]  B. Gusterson,et al.  Expression of p53 in premalignant and malignant squamous epithelium. , 1991, Oncogene.

[26]  V. Rotter,et al.  Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. , 1991, Cancer research.

[27]  J. Bartek,et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.

[28]  R. Martuza,et al.  TP53 Gene Mutations and 17p Deletions in Human Astrocytomas , 1991, Genes, chromosomes & cancer.

[29]  M. Willingham,et al.  Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[30]  C. Midgley,et al.  p53 immunostaining as a marker of malignant disease in diagnostic cytopathology , 1991, The Lancet.

[31]  C. Wolkow,et al.  Levels of p53 protein increase with maturation in human hematopoietic cells. , 1991, Cancer research.

[32]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[33]  R. Schlegel,et al.  p53 in the diagnosis of human neoplasia. , 1991, Journal of the National Cancer Institute.

[34]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[35]  J. Marks,et al.  Maintenance of p53 alterations throughout breast cancer progression. , 1991, Cancer research.

[36]  B. Ljung,et al.  Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[37]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Harris.  Mutant p53—the commonest genetic abnormality in human cancer? , 1990, The Journal of pathology.

[39]  E. Appella,et al.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Bartek,et al.  Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. , 1990, Oncogene.

[41]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[42]  A. Harris,et al.  Increased expression of mutant forms of p53 oncogene in primary lung cancer , 1990, The Lancet.

[43]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[44]  G. Cattoretti,et al.  P53 and oncogenes expression in psoriasis. , 1989, Acta dermato-venereologica. Supplementum.

[45]  F. Rilke,et al.  P53 expression in breast cancer , 1988, International journal of cancer.

[46]  L. Banks,et al.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. , 1986, European journal of biochemistry.

[47]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.